Document is current
Any future updates will be listed below
-
Authors
Joshi, Amit U https://orcid.org/0000-0002-2472-7672
Saw, Nay L
Vogel, Hannes
Cunnigham, Anna D
Shamloo, Mehrdad
Mochly‐Rosen, Daria https://orcid.org/0000-0002-6691-8733
-
Funding
Funding for this research was provided by:
HHS | NIH | National Institute of Neurological Disorders and Stroke (NS069375)
Stanford University School of Medicine
Takeda Pharmaceuticals U.S.A.
- License Information
-
More Information
Article History
Received: 19 June 2017
Revised: 11 December 2017
Accepted: 18 December 2017
First Online: 15 January 2018
Conflict of interest
: Patents on P110 and its utility in HD, ALS and other neurodegenerative diseases have been filed by DM‐R and AUJ, and P110 was recently licensed to Mitoconix Bioscience, a company that DM‐R founded and serves on its board, that develops new treatment for Huntington's disease. However, none of the work in her laboratory was carried out in collaboration with or with financial support from the company. AUJ and MS both advised the company, as part of technology transfer to the company, on their work related to Huntington's disease. The other authors declare that they have no conflict of interest.
